Ex Vivo Expansion of Dendritic Cells for Breast Cancer Treatment
Abstract
The overall goal of this project was to develop a clinical-grade serum-free medium that specifically supported dendritic cell (DC) formation and antigen presentation. In two separate series of experiments we have characterized a serum-free medium that supports the ex vivo proliferation of DCs as well as their antigen presenting ability. In the first series of experiments we used CD34+ cells derived from mobilized peripheral blood stem cells and differentiated them to DCs in the presence of the cytokines GM-CSF, IL-4 and TNFalpha, although the serum-free medium supported this process it yielded only a small percentage of the DCs (3-5%) that are too few in number for clinical protocols. In a second series of experiments we used this same QBI serum-free formulation and differentiated DCs from normal monocytes that yielded over 80% of the population positive for the DC immunophenotype. This compared nearly equivalent in both number and antigen presenting ability to a proprietary serum-free medium developed specifically for lymphocyte proliferation and used in DC clinical trials. Future experiments are designed at optimizing this medium and evaluating other nutritional factors, cytokines and culture conditions to yield optimal DCs both in terms of number and function.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2002
- Accession Number
- ADB282793
Entities
People
- Ronald L. Brown